Introduction
Numerous reports have demonstrated that the single most important predictor of engraftment following autologous stem cell transplantation (ASCT) is the CD34 þ dose, with minimum and preferred targets of 2.0 Â 10 6 and 5.0 Â 10 6 cells/kg, respectively. 1, 2 In order to achieve these targets, multiple apheresis procedures may be required. Cryopreservation of the autograft is usually carried out within 2-4 h following the collection. Current cryopreservation practices are technically demanding and may require experienced laboratory personnel to work extended hours in order to process samples on the day of collection. As such, costs and inconvenience are concerning.
A number of in vitro experiments have shown that storage of peripheral blood stem cells (PBSC) for short periods of time does not adversely affect stem cell viability or engraftment potential. [3] [4] [5] [6] Storage beyond a period of 24-72 h has been associated with decreased nucleated cell viability, decreased glucose concentration and increased pH. 7 It would seem that storage beyond this 24-72 h time period risks suboptimal hematopoietic re-constitution. In 1998, Sugrue et al. 8 demonstrated 100% cell viability and 99.5% cell recovery in samples stored at a median temperature of 151C overnight without an adverse effect on engraftment in a sample of 12 patients whose overnight stored product was batched with next-day leukapheresis product. This translated into a cost saving of 33%.
In March 2000, Lazarus et al. 9 published a small randomized trial demonstrating that overnight storage of purged autografts did not adversely impact early engraftment of lymphoma patients undergoing ASCT compared to traditionally processed purged autografts. Thereafter, our center adopted next-day autograft cryopreservation into routine clinical practice. The potential impact of nextday cryopreservation of unpurged autografts on short-term and long-term clinical outcome has not previously been reported. In this retrospective study of lymphoma patients receiving a single, unpurged ASCT, we compare outcomes of immediate cryopreservation of autologous PBSC grafts with those of next-day autograft cryopreservation after overnight storage at 2-61C in terms of time to early engraftment post-ASCT, frequency of low blood counts 6 months post-ASCT, as well as relapse-free survival (RFS) and overall survival (OS).
Patients and methods

Study population
A retrospective analysis of all 229 (age 18-69 years) consecutive individuals treated with a single, unpurged ASCT for Hodgkin's disease or non-Hodgkin's lymphoma (NHL) in Calgary between January 1995 and November 2003 was performed. The November 2003 date was chosen to give a minimum follow-up of 18 months post-ASCT at the time of initiating this retrospective study. Of these patients, 131 consecutive patients before September 2000 underwent ASCT with immediate cryopreservation of the leukapheresis product. From September 2000 to November 2003, a further 98 consecutive patients underwent ASCT using a leukapheresis product that was stored overnight at 41C before processing and cryopreservation. All patients gave written informed consent for autologous PBSC apheresis, autograft cryopreservation, ASCT and data collection in the Calgary BMT database. Overnight autograft storage before cryopreservation was a standard practice policy change in September 2000, not part of a prospective clinical trial. As such, Research Ethics Board approval was not obtained for next-day cryopreservation. This retrospective study was conducted as a quality assurance project to ensure that the policy change was not adversely impacting patient outcome.
Mobilization and collection of PBSC
Patients underwent combined chemotherapy plus granulocyte colony-stimulating factor (G-CSF) treatment for PBSC mobilization. The most commonly used re-induction and PBSC mobilization regimen for lymphoma in Calgary is DICEP (dose-intensive cyclophosphamide 5.25 g/m 2 , etoposide 1.05 g/m 2 and cisplatin 105 mg/m 2 ) plus G-CSF (300 mg/day if body weight o60 kg, 480 mg/day if weight 60-90 kg or 600 mg/day if weight 490 kg). Other lower intensity regimens were used for patients who had a minimal tumor burden, marrow biopsies free of contaminating lymphoma, significant co-morbid diseases or if they were enrolled on a clinical trial that mandated a particular chemotherapy regimen. Leukapheresis was initiated when the blood CD34 þ count was at least X10 Â 10 6 /l, white blood cells (WBC) X5 Â 10 9 /l and platelets X50 Â 10 9 /l. Leukapheresis for all patients was performed using a CobeSpectra, cell separator (Cobe Canada, Scarborough, Ontario, Canada) using a continuous collection procedure according to the manufacturer's protocols for mononuclear harvesting. Venous access was through a double or triple lumen dialysis catheter inserted into the internal jugular vein. Products were targeted to achieve a minimum of X2.0 Â 10 6 CD34 þ cells/kg and a preferred X5.0 Â 10 6 CD34 þ cells/kg.
Overnight storage and processing PBSC
The autologous PBSC leukapheresis products of patients who underwent mobilization before September 2000 were immediately processed and cryopreserved as described previously. 1 Briefly, PBSC were volume adjusted to a final concentration of o3 Â 10 8 nucleated cells/ml. Dimethylsulfoxide (DMSO), 5% albumin or plasma, and either tissue culture medium TC 199 (before September 2004) or Plasma-Lyte A (after September 2004) were mixed with the PBSC apheresis product to achieve a 10% DMSO final concentration. The processed suspension was transferred into Baxter freezing bags and rate control frozen to À901C. Following the change in laboratory practice in September 2000, the PBSC leukapheresis products were stored overnight in the gas permeable Baxter collection bags at 2-61C and processed the following day using the same technique described above. Cell concentrations were not diluted or otherwise altered before overnight storage. Viability testing was performed for a subset of 27 patients before and after overnight storage using flow cytometric evaluation of CD34 þ cells with 7-amino-actinomycin D (7-AAD) staining (Immunotech, a Beckman Coulter Company, Marseille, France). CD34 þ counts were not routinely performed before and after overnight storage, and assays for clonogenic capacity were not performed. Bacterial cultures were performed on all apheresis products before cryopreservation and again post-thaw before infusion. The apheresis nurse collected the pre-cyropreservation bacterial culture samples from the apheresis product. If the product was stored overnight, the culture samples were also stored overnight and processed the next day.
Statistical methodology
Comparisons between the two groups, immediate vs delayed processing, were performed using standard statistical means using Stata version 8.0. (Stata Corp., College Station, TX, USA). Platelet and neutrophil engraftment were defined as the first of three consecutive days that platelets were 420 Â 10 9 /l and absolute neutrophil count (ANC) 40.5 Â 10 9 /l. We performed a w 2 test of association to assess for statistical differences in platelet and neutrophil recovery between the two groups and hematologic reconstitution at 6 months post transplant. To test for impact of storage, Fisher's exact test and t-tests were performed.
Univariate analyses were performed using a Cox proportional hazard model of variance in conjunction with simple regression, for the following potential predictors of engraftment and clinical outcome: immediate or next-day autograft cryopreservation, CD34 þ cell dose/kg, age, gender, tumor type, disease status, prior therapy and high-dose regimen. Multiple regression analysis was then used to study the effect of a predictor with other variables being simultaneously controlled.
Results
Patient characteristics
The clinical characteristics of the two patient groups are summarized in Table 1 . All adult patients (age X18 years) who underwent ASCT for either NHL or Hodgkin's disease were included in this analysis. One hundred twenty-eight patients (56%) enrolled had aggressive NHL, 55 (24%) indolent NHL and 46 (20%) with Hodgkin's disease. The two groups of patients were similar with respect to age, sex, underlying diagnosis and CD34 þ stem cell dose. The disease status and associated number of prior chemotherapy regimens, and the high-dose chemotherapy regimens use for ASCT were statistically different between groups.
Viability testing and bacterial culture of apheresis products Viability testing of CD34 þ cells using flow cytometry and 7-AAD dye for a subset of autografts that underwent next-day cryopreservation demonstrated 91-100% viability (median 99%), with absolutely identical results before and after overnight storage. In the immediate cryopreservation group before September 2000, none of the bacterial cultures were positive post-apheresis and only two (2.0%) were positive post-thaw (Enterobacter agglomerans and Grampositive bacilli and cocci). In the overnight storage group after September 2000, one (0.8%) of the bacterial cultures was positive post-apheresis (Gram-positive bacilli) and three (2.3%) were positive post-thaw (one with Bacillus sp and two Gram-positive cocci).
Early hematopoietic engraftment post-ASCT Hematopoietic engraftment by timing of autograft cryopreservation is summarized in Table 2 . Median and mean times to platelet recovery 420 Â 10 9 /l occurred 1 and 2.5 days earlier, respectively in the overnight storage/next-day cryopreservation group (95% confidence interval (CI) of difference in means 1.1-3.9, P ¼ 0.0007). When organized into arbitrarily defined categories, the frequency of early (p9 day), intermediate (10-13 days) and delayed (X14 days), platelet engraftment was 35, 62 and 3%, respectively for patients who received next-day cryopreserved autografts, compared to 14, 68 and 18%, respectively for patients who received immediately cryopreserved autografts (Po0.0001). Median and mean times to ANC recovery 40.5 Â 10 9 /l occurred 1 and 0.8 days earlier, respectively in the overnight storage/next-day cryopreser- Hematopoietic reconstitution at 6 months post transplantation Table 2 summarizes the proportion of patients who had blood counts below the lower limit of normal 6 months post-ASCT according to timing of autograft cryopreservation. By multivariate, logistic regression analysis, there was no statistically significant association between immediate or next-day autograft cryopreservation and the proportion of individuals who had a normal platelet count 4150 Â 10 9 /l 6 months post-ASCT (P ¼ 0.22), hemoglobin levels 4120g/l (P ¼ 0.15) or WBC 44.0 Â 10 9 /l (P ¼ 0.18). This logistic regression analysis detected an association between older age (odds ratio (OR) 1.05, Po0.001) and male gender (OR 2.43, P ¼ 0.006) and low hemoglobin levels, as well as between lower CD34 þ cell dose/kg (OR 1.06, P ¼ 0.005) and low platelet counts 6 months post-ASCT. Linear regression analysis was also performed using actual observed blood counts 6 months post-ASCT (results not shown) and gave results consistent with those of the logistic regression. Although long-term transfusion dependence was not assessed directly, the number of individuals with significantly reduced hemoglobin o80 g/l (1/89 (1%) vs 0/106 (0%), P ¼ 0.456) or platelets o50 Â 10 9 /l (1/89 (1%) vs 4/106 (4%), P ¼ 0.378) did not differ between groups. Regarding OS, a single covariate Cox proportional hazard model revealed a nonsignificant HR of 0.68 for overnight autograft storage (95%CI 0.39-1.17, P ¼ 0.16) indicating that timing of autograft cryopreservation was not a predictor of death. By multivariate analysis, factors independently associated with higher risk of death post-ASCT were aggressive NHL (HR 2.60; 95%CI 1.01-6.65, P ¼ 0.047) relative to Hodgkin's disease, relapsed (HR 2.68; 95%CI 1.33-5.37, P ¼ 0.006) and refractory (HR 3.76; 95%CI 1.71-8.26, P ¼ 0.001) disease status relative to first remission, use of total body irradiation (TBI) (HR 2.30; 95%CI 1.12-4.73, P ¼ 0.02) and age (HR 1.05; 95%CI 1.02-1.08, Po0.0001). The HR of 1.049 for age indicates that a 1-year increase in age was associated with a 4.9% increase in the relative risk of dying post-ASCT.
RFS and OS
Discussion
Myeloablative chemotherapy and ASCT is increasingly used to improve outcomes of patients with relapsed or poor prognosis lymphoma. However, given the frequent requirement for multiple apheresis procedures in order to attain the minimally acceptable CD34 þ cell dose for ASCT, cost and inconvenience of autograft collection and cryopreservation are of concern.
10 Immediate autograft processing and cryopreservation has been the standard policy at many centers with the assumption that this maximizes autograft viability. 11 In Calgary, because of the increasing use of ASCT, restraints on the healthcare system and the study published by Lazarus et al. 9 demonstrating feasibility of next-day cryopreservation, we changed policy in September 2000 and began storing autografts overnight before cryopreservation. This change in policy allowed single but more prolonged, high volume leukapheresis and efficient time utilization by laboratory personnel.
The results of our study suggest that storage of autologous PBSC grafts at 2-61C overnight before processing and cryopreservation does not have a deleterious impact on early engraftment, blood counts 6 months post-ASCT, relapse rates or OS. In fact, the rate of early engraftment was significantly faster in patients who received next-day cryopreserved autografts compared to the immediately processed autografts. Although this finding was likely due to the use of historical controls in this retrospective study, the association between overnight autograft storage and more rapid early engraftment persisted despite controlling for differences in patient characteristics and treatment protocols between study groups in multivariate analysis. Another, albeit less likely, and unsubstantiated explanation for this finding is possible ex vivo expansion of the autograft through overnight storage before cryopreservation. 12, 13 The retrospective, observational nature of this study introduces several inherent limitations. The patient populations were heterogeneous with respect to diagnosis and disease status. Newer technologies and supportive mechanisms have been developed that may have positively influenced outcome of the more recently treated group receiving next-day cryopreserved autografts. The conditioning regimens were significantly different between the two groups, with a change from melphalan/TBI during the time of immediate autograft cryopreservation, to BEAM (carmustine, etoposide, ara-C, melphalan) during the more recent next-day autograft cryopreservation. Although this change in conditioning regimen may influence long-term outcomes such as relapse and death, it is unlikely to affect engraftment rates.
Predictors of engraftment recognized in the literature are predominantly the number of CD34 þ cells infused and prior alkylator therapy. [14] [15] [16] [17] In the present study, CD34 þ dose correlated with time to platelet and neutrophil recovery. Other independent predictors for neutrophil but not platelet recovery identified in this study include female gender and absence of either refractory or relapsed disease. This study confirms a previous report that overnight storage of stem cells does not adversely impact engraftment potential. 9 It needs to be emphasized, however, that both groups received fairly large CD34 þ cell doses, and that we cannot exclude an adverse effect of overnight autograft storage before cryopreservation in the setting of a small CD34 þ cell dose. Only two patients in our overnight autograft storage group received ASCT with o3 Â 10 6 CD34 þ cells/kg and only five received 3-5 Â 10 6 CD34 þ cells/kg. This seven-patient sample size is too small to analyze and draw statistical conclusions regarding engraftment kinetics. Of interest, in multivariate analyses evaluating the association between CD34 þ cell dose/kg and engraftment, the HRs were close to 1.0, probably because the vast majority of patients in the study received ASCT with 45 Â 10 6 CD34 þ cells/kg, and also because all patients received G-CSF post-ASCT to hasten ANC recovery.
Two previously reported studies have assessed the impact of overnight storage of autografts that had been subjected to purging with CD34 þ selection. Koc et al.
18 using immuno-affinity columns directed against CD34 þ assessed the effect of overnight storage of positively selected PBSC of 11 patients against historical controls and found no difference in time to neutrophil recovery (11 days), however, there was significant delay in platelet recovery (13 vs 28.5 days). Samples stored overnight had a mean of 2.4-fold less CD34 þ cells infused suggesting potential loss or differentiation. In 2000, Lazarus et al. 9 reported a randomized control trial of 53 patients to assess the impact of overnight storage on positively selected autografts. In this study, there was no significant difference in days to neutrophil recovery (10.5 vs 11) or platelet recovery (13.5 vs 13). Of note, CD34 þ selection is a technically laborious process, associated with increased cost, and has not been proven to improve clinical outcome of ASCT. 19 RFS and OS were evaluated in this study assessing overnight autograft storage before cryopreservation because we have reported that CD34 þ dose influences both relapse and death, 14 and because there is a theoretical potential for decrease in tumor contamination with overnight storage as cancerous cells have decreased ex vivo survival. 20 As far as we have been able to determine, this is the first study which has demonstrated that there is not a correlation between overnight autograft storage before cryopreservation and RFS or OS. As expected, factors we found to be most strongly associated with inferior RFS and OS were diagnosis of aggressive NHL, as well as relapsed or refractory disease status.
In conclusion, this study demonstrates that PBSC autografts containing 45 Â 10 6 CD34 þ cells/kg can be safely stored overnight at 2-61C, without adversely effecting the time to early engraftment, blood counts 6 months post-ASCT, RFS or OS. It is important to establish whether the same is true for products of between 2 and 5 Â 10 6 CD34 þ cells/kg. The use of next-day autograft cryopreservation allows large volume apheresis to proceed later in the day, gives time for assessment of tumor contamination before cryopreservation if one desires, and permits staff to process and freeze the autograft in a convenient, cost-effective manner. We suggest that centers considering a change in policy to overnight autograft storage before cryopreservation execute a validation protocol comparing fresh and overnight stored apheresis products for CD34 þ counts, tests for viability and possibly clonogenic capacity. This is particularly important for centers that have a significant proportion of autografts containing o5 Â 10 6 CD34 þ cells/kg.
